Lennox-Gastaut Syndrome (LGS) Market

Lennox-Gastaut Syndrome (LGS) is considered as an epileptic encephalopathy and is defined by a triplet of multiple drug-resistant seizure types, a specific EEG configuration presenting bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual disability.

As per DelveInsight estimates, total diagnosed prevalent cases of LGS in the 7MM was found to be 68,811 in 2017. Among all the countries, the estimates show a higher population of LGS in the United States with 31,925 cases in 2017.

Among the EU5 countries, the UK had the highest diagnosed prevalent population of LGS with 13,082 cases, followed by France. On the other hand, Spain had the lowest prevalent population.

As per DelveInsight estimates, among the 7MM, Japan had the lowest diagnosed prevalent population of LGS in 2017.

For more information on Lennox-Gastaut Syndrome (LGS) Market, visit:
https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market